Entero Healthcare: Jefferies lifts target to INR 1,350

What changed in Jefferies’ latest note

Jefferies raised its price target on Entero Healthcare Solutions to INR 1,350 from INR 1,320 and maintained its Buy rating, according to a Feb. 16 update. The revision follows an earlier upgrade where Jefferies moved the stock from Hold to Buy and lifted the target to INR 1,320 from INR 1,250. The brokerage framed the change around a view that market expectations have reset after a period of share underperformance. Entero’s stock had declined about 20% over the past 12 months, compared with a roughly 3% drop in the Nifty Pharma Index. Jefferies also noted the stock was trading about 13% below its February 2024 IPO price of INR 1,258 at the time of the upgrade. The latest target revision to INR 1,350 keeps the focus on earnings visibility, execution, and the company’s acquisition approach.

How the rating moved from Hold to Buy

The Investing.com note captured Jefferies’ earlier stance change from Hold to Buy, alongside a higher target of INR 1,320 from INR 1,250. Jefferies linked the stock’s weak relative performance to lower-than-expected revenue growth and margins. It attributed this to Entero adopting a more selective approach to acquisitions than the market had anticipated. The brokerage’s argument was that selectivity may have weighed on near-term growth and profitability optics, but could help improve margins if executed well. The re-rating to Buy effectively signals that Jefferies believes the downside from past disappointment is better reflected in the share price. The follow-on adjustment to INR 1,350 from INR 1,320 continued that line of thinking, without changing the Buy recommendation.

Valuation markers Jefferies highlighted

Jefferies cited Entero’s price-to-earnings valuations of 34x, 28x, and 21x for fiscal years 2026, 2027, and 2028, respectively. These figures were presented as part of the case that expectations are now more grounded. The firm’s framing suggests valuation is being assessed against a medium-term growth outlook rather than a single-year rebound. While the note did not provide earnings numbers, it explicitly laid out the P/E trajectory across FY26 to FY28. The brokerage also set out an operating view where acquisitions, and how selective the company is in pursuing them, can influence margin delivery. That combination of valuation and execution is central to its Buy thesis as described in the provided text.

Organic growth and acquisitions: the operating thesis

Jefferies said it expects Entero to achieve organic growth of at least 1.5 times the industry rate over the medium term. It also stated that the company’s more selective acquisition strategy could deliver improved margins. At the same time, it linked earlier underperformance to this selectivity, implying the market had priced in a faster or broader acquisition-led expansion. The note therefore sets up a trade-off investors track closely in roll-up or distribution-led healthcare models: growth pace versus quality of assets and margin sustainability. Jefferies did not quantify the industry growth baseline in the provided excerpt, but it did give a clear relative benchmark (1.5 times the industry rate). The brokerage’s view is that, after a reset in expectations, this strategy can be better appreciated by the market.

A look back at earlier Jefferies actions on the stock

The provided timeline shows multiple target and rating changes through 2024 to 2026, with large adjustments around FY26 expectations and quarterly performance. In May 2025, Jefferies downgraded Entero to Hold from Buy and cut the price target by 20% to INR 1,320 from INR 1,650, with the stock falling about 3% to INR 1,303 on the day. Later in August 2025, Jefferies adjusted its target to INR 1,350 from INR 1,320 while keeping a Hold rating (as shown in the chronology). In November 2025, it reduced the target to INR 1,250 from INR 1,350 and maintained Hold. By February 2026, the firm had moved back to a more constructive stance, first upgrading to Buy with INR 1,320 and then lifting to INR 1,350 while keeping Buy. The sequence reflects a rating cycle shaped by delivery versus expectations, especially on growth and margins.

Key data points in one place

What the May 2025 downgrade cited

The May 2025 note highlighted a mismatch between results, forecasts, and broker expectations. It stated that Entero’s Q4 revenue and profit after tax jumped 29% and 23% year-on-year, respectively. Even with that growth, Jefferies said Q4 profit and revenue were 6% below its estimates, and that the FY26 forecast was “lower than expected.” The brokerage estimated 34% revenue growth in FY26, while the company guided for more than a 30% increase. Jefferies also flagged a slower-than-expected pace of acquisitions and sluggish organic growth. It said Entero’s expectation setting and delivery had been “checkered” so far, and the stock was down about 9% year-to-date at that time.

Market context: prices, ranges, and consensus targets

The provided market snapshot shows Entero trading across a 52-week range of INR 991.10 to INR 1,584.25, with one cited close at INR 1,380.30 (up 5.18%) and a day range of INR 1,292.20 to INR 1,425.00. Another data line shows INR 1,086.50 with a -1.01% move on that day, alongside other period-change figures in the feed. Separately, LSEG-compiled data cited in the May 2025 note said the stock had an average rating of Buy with a median price target of INR 1,481. A separate consensus snapshot in the text shows an average 12-month price target of INR 1,595.50 from four analysts, with targets ranging between INR 1,500 and INR 1,650. These figures provide context for Jefferies’ INR 1,350 target, which sits below the average target shown in the consensus data.

Why this matters for investors tracking the stock

Jefferies’ shift to Buy and the incremental target hike to INR 1,350 matters because it ties together three issues investors have been debating: growth pace, margin delivery, and acquisition execution. The brokerage’s explanation suggests the market penalised Entero for revenue growth and margin outcomes that fell short of earlier expectations. It also signals that, after the stock’s decline and the reset in expectations, Jefferies sees the risk-reward as improved at the valuation levels it cited. The emphasis on organic growth running at least 1.5 times the industry rate places attention on underlying business traction, not only deal-driven scale. At the same time, the May 2025 downgrade shows how sensitive the stock can be to forecast gaps, even when year-on-year growth is strong. For investors, the immediate takeaway is that Jefferies is again positioning Entero as a Buy, but with a thesis that leans on disciplined acquisitions and a clearer path to better margins.

Conclusion

Jefferies has maintained its Buy on Entero Healthcare Solutions and lifted its price target to INR 1,350 from INR 1,320 in its Feb. 16 update, following an earlier upgrade from Hold to Buy. The brokerage has framed the call around reset market expectations, valuation levels across FY26 to FY28, and the potential margin benefits of a more selective acquisition strategy. Earlier notes show that delivery versus expectations, especially on FY26 growth and acquisition pace, has driven sharp changes in Jefferies’ stance. The next set of company updates and any confirmation of growth and margin progress will remain key reference points for how this Buy view plays out.